(Q37370649)

English

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

scientific article published on 24 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

Robert Peter Gale

13

object named as

Robert Peter Gale

1 reference

Europe PubMed Central

20 August 2017

Jorge Eduardo Cortes

35

object named as

Jorge Cortes

1 reference

Europe PubMed Central

20 August 2017

27

object named as

Harry C Schouten

1 reference

Europe PubMed Central

20 August 2017

Alison Wakoff Loren

20

object named as

Alison W Loren

1 reference

Europe PubMed Central

20 August 2017

19

object named as

Mark R Litzow

1 reference

Europe PubMed Central

20 August 2017

Koen van Besien

8

object named as

Koen van Besien

1 reference

Europe PubMed Central

20 August 2017

author name string

Edward A Copelan

1

1 reference

Europe PubMed Central

20 August 2017

Betty K Hamilton

2

1 reference

Europe PubMed Central

20 August 2017

Belinda Avalos

3

1 reference

Europe PubMed Central

20 August 2017

Kwang Woo Ahn

4

1 reference

Europe PubMed Central

20 August 2017

Brian J Bolwell

5

1 reference

Europe PubMed Central

20 August 2017

Xiaochun Zhu

6

1 reference

Europe PubMed Central

20 August 2017

Mahmoud Aljurf

7

1 reference

Europe PubMed Central

20 August 2017

Christopher Bredeson

9

1 reference

Europe PubMed Central

20 August 2017

Jean-Yves Cahn

10

1 reference

Europe PubMed Central

20 August 2017

Luciano J Costa

11

1 reference

Europe PubMed Central

20 August 2017

Marcos de Lima

12

1 reference

Europe PubMed Central

20 August 2017

Gregory A Hale

14

1 reference

Europe PubMed Central

20 August 2017

Joerg Halter

15

1 reference

Europe PubMed Central

20 August 2017

Mehdi Hamadani

16

1 reference

Europe PubMed Central

20 August 2017

Yoshihiro Inamoto

17

1 reference

Europe PubMed Central

20 August 2017

Rammurti T Kamble

18

1 reference

Europe PubMed Central

20 August 2017

David I Marks

21

1 reference

Europe PubMed Central

20 August 2017

Eduardo Olavarria

22

1 reference

Europe PubMed Central

20 August 2017

Vivek Roy

23

1 reference

Europe PubMed Central

20 August 2017

Mitchell Sabloff

24

1 reference

Europe PubMed Central

20 August 2017

Bipin N Savani

25

1 reference

Europe PubMed Central

20 August 2017

Matthew Seftel

26

1 reference

Europe PubMed Central

20 August 2017

Celalettin Ustun

28

1 reference

Europe PubMed Central

20 August 2017

Edmund K Waller

29

1 reference

Europe PubMed Central

20 August 2017

Daniel J Weisdorf

30

1 reference

Europe PubMed Central

20 August 2017

Baldeep Wirk

31

1 reference

Europe PubMed Central

20 August 2017

Mary M Horowitz

32

1 reference

Europe PubMed Central

20 August 2017

Mukta Arora

33

1 reference

Europe PubMed Central

20 August 2017

Jeff Szer

34

1 reference

Europe PubMed Central

20 August 2017

Matt E Kalaycio

36

1 reference

Europe PubMed Central

20 August 2017

Richard T Maziarz

37

1 reference

Europe PubMed Central

20 August 2017

Wael Saber

38

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

24 September 2013

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

122

1 reference

Europe PubMed Central

20 August 2017

3863-3870

1 reference

Europe PubMed Central

20 August 2017

24

1 reference

Europe PubMed Central

20 August 2017

Reduced mortality after allogeneic hematopoietic-cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Hematopoietic stem-cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Myeloablative conditioning regimens for AML allografts: 30 years later

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Nonmalignant late effects after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

An X chromosome gene regulates hematopoietic stem cell kinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Score test of homogeneity for survival data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

6 September 2017

Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

14 September 2017

The chemical and biological properties of busulphan ("Myleran").

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

14 September 2017

Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

28 September 2017

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

26 June 2018

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

26 June 2018

Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

The impact of low-dose busulfan on clonal dynamics in nonhuman primates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3854108

2 September 2018

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and metabolic studies of high-dose busulphan in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osse

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (S

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Trans

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065243

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2013-07-514448

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37370649&oldid=1810100471"